Lilly Taps Investment Firm To Help Fund Phase III Alzheimer’s Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly retains ownership and control over compounds; deal frees resources for development of other pipeline molecules.
You may also be interested in...
Blinding Them With Science: Genentech Tries To Win Shareholders Over
Genentech's March 2 presentation to analysts and investors - a four hour plus love-in dominated by talk of peptides and pathways - seems to have worked
Blinding Them With Science: Genentech Tries To Win Shareholders Over
Genentech's March 2 presentation to analysts and investors - a four hour plus love-in dominated by talk of peptides and pathways - seems to have worked
Whatever Works – Or Might: Pfizer/Wyeth May Keep Both Alzheimer’s Bets
Sources close to the situation say the merged Pfizer/Wyeth entity will probably maintain ongoing Phase III development programs for both dimebon, the Alzheimer's disease medicine Pfizer in-licensed earlier this year, and bapineuzumab, the antibody being tested by Wyeth and Elan. And the reason has as much to do with the much-bandied "shots on goal" strategy as with efficacy signals exhibited so far by either drug